

Medicines and Medical Devices Bill

AMENDMENT
TO BE MOVED
IN GRAND COMMITTEE

Clause 1

LORD HUNT OF KINGS HEATH

Page 1, line 12, at end insert—

“() In subsection (2)(c), “attractiveness” means favourability for—

- (a) the conduct of clinical trials of and research into new medicines, including for rare diseases;
- (b) establishing expertise and forging international regulatory standards in areas of strategic importance to the United Kingdom, including cell and gene therapy;
- (c) collaborating with the European Medicines Agency and other international regulators;
- (d) conducting discussions regarding reimbursement in parallel with the process of granting marketing authorisations for new medicines; or
- (e) facilitating prompt access to new medicines once they have been approved through the implementation of new approaches to reimbursement.”

Member’s explanatory statement

This amendment provides a definition of attractiveness for clarity.

Medicines and Medical Devices Bill

AMENDMENT
TO BE MOVED
IN GRAND COMMITTEE

16 September 2020
